EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer

Cheng-Yu Chang, Yu-Feng Wei, Shih-Chieh Chang iD, Chung-Yu Chen

Current Oncology · 2025

DOI: 10.3390/curroncol32080472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Cheng-Yu Chang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220216, Taiwan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Small Cell Lung Carcinoma, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Extensive-stage small cell lung cancer (ES-SCLC) has poor prognosis. While immune checkpoint inhibitors (ICIs) with chemotherapy show survival benefits in trials, real-world data from Asia are scarce. This study evaluates real-world efficacy and safety of chemotherapy with or without ICIs in Taiwanese patients with ES-SCLC and identifies survival predictors. Materials and Methods: A retrospective cohort study analyzed 114 patients with ES-SCLC treated between 2017 and 2023 at four Taiwanese medical centers. Patients received first-line chemotherapy alone (n = 68) or with ICIs (atezolizumab, durvalumab, pembrolizumab; n = 46). Primary endpoints were overall survival (OS) and progression-free survival (PFS), assessed via Kaplan–Meier methods and Cox regression.

Results

Baseline characteristics were comparable, except poorer ECOG performance (≥2) in the chemotherapy group (27% vs. 9%; p = 0.021). IO–chemotherapy significantly improved OS (16.1 vs. 9.4 months; HR = 0.32, 95% CI: 0.20–0.52; p < 0.001) and PFS (7.8 vs. 5.5 months; HR = 0.40, 95% CI: 0.26–0.63; p < 0.001). Multivariate analysis confirmed IO–chemotherapy as an independent positive predictor (OS adjusted HR = 0.25, 95% CI: 0.14–0.44; PFS adjusted HR = 0.37, 95% CI: 0.22–0.61; both p < 0.001). Skin rash was more common with IO–chemotherapy (24% vs. 3%; p < 0.001). Immune-related adverse events (AEs) correlated with improved survival (median OS: 21.4 months with 1–2 AEs, 16.6 months with 3–4 AEs, 12.5 months without AEs).

Conclusion

Immunochemotherapy significantly improves survival in Taiwanese patients with ES-SCLC, with manageable toxicity, supporting ICIs’ incorporation into standard treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsSmall Cell Lung CarcinomaLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleTaiwanMiddle AgedAgedRetrospective StudiesNeoplasm StagingAdultTreatment Outcome

Stichwörter der Autor:innen

chemotherapyimmunotherapyreal-worldsmall cell lung cancersurvival

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220216, Taiwan.
  • Department of Electrical Engineering, Yuan Ze University, Taoyuan City 32003, Taiwan.
  • Department of Internal Medicine, E-Da Cancer Hospital, Kaohsiung 82445, Taiwan.
  • School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan.
  • Division of Chest Medicine, Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital, Yilan 260006, Taiwan.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County 64002, Taiwan.

ORCID-Profile: Shih-Chieh Chang

Zitieren

APA

Chang, C. Y., Wei, Y. F., Chang, S. C., & Chen, C. Y. (2025). Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer. Current Oncology. https://doi.org/10.3390/curroncol32080472

Vancouver

Chang CY, Wei YF, Chang SC, Chen CY. Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer. Current Oncology. 2025. doi:10.3390/curroncol32080472

BibTeX
@article{Chang2025,
  author = {Chang, Cheng-Yu and Wei, Yu-Feng and Chang, Shih-Chieh and Chen, Chung-Yu},
  title = {Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32080472}
}
Kostenlos starten →